“Capella Bioscience is happy with the partnership with FairJourney Biologics for being capital efficient. Such a big antibody discovery team gives us the peace of mind, knowing that they have enough expertize to work with us.”
Steve Holmes
COO, Capella Bioscience
“I strongly recommend FairJourney Biologics for the Service of sequencing mAb variable domains. They have performed an outstanding work solving all the technical problems in a reasonable period of time. Moreover, they have provided a great quality-price ratio.”
Dr. Jesús Salvador
Assistant Professor,
National Center for Biotechnology, CNB-CSIC
“I had the opportunity to work with FairJourney Biologics since last year and I am impressed by the skills and speed the different projects are delivered. I was personally involved in a project in summer 2013 in which we pulled out together 121 leads of highly specific antibodies in just 3 days. Moreover, the whole teams respires such a enthusiasm that it is a pleasure to work with FairJourney Biologics and I can recommend them to anyone looking for desired new antibodies.”
John Wijdenes
Mabdesign and CEO
and consultant, AD&T consultancy
“The experienced team of FairJourney Biologics worked with us in a very pleasant and collaborative way to develop several assay tools. They demonstrated to be very flexible and delivered on time.”
Arnout Gerritsen
Associate Director,
Assay and Bioanalytical Science at Genmab
“FairJourney Biologics has demonstrated the capacity to deliver high quality antibody engineering services. The team is very experienced in phage display for the discovery of antibodies from rodent immune repertoires for diagnostic and therapeutic applications. Humanization is performed by affinity driven selections of libraries to avoid loss in potency. Desired specificity and optimal affinities can be achieved by applying appropriate selection methods thereby delivering leads useful for the development of highly specific and sensitive diagnostic assays. The outstanding track record of its research team, has enable the company to provide us with new antibodies with excellent characteristics.”
Hans de Haard
“Many thanks to FairJourney Biologics for their invaluable help to design, develop and successfully qualify our potency ELISA assay. FJB even arranged on-site support for the transfer to our GMP manufacturing and testing site!”
Paul da Silva Jardine
Co-founder and CSO,
Staten Biotechnology B.V.
“I was impressed by the remarkable efficacy, rapidity and smoothness of the service provided by FairJourney Biologics: 14 days between the hybridoma cells leaving our lab, and reception of the variable domain sequences! With scientists at FairJourney always readily answering all questions we had about the project. Very fruitful experience!”
Prof. Sophie Lucas
de Duve Institute Université catholique
de Louvain Brussels, Belgium
“FairJourney Biologics has shown excellent performance in a challenging project. Their team has demonstrated to be focused on guarantying high-quality results in a competitive timeframe and at an affordable cost.”
CEO, Complix
“FairJourney Biologics generated a comprehensive data package for a Viridian project, whereby they expressed, purified and characterized 17 lead antibody constructs. The characterization included biophysical properties, accelerated stability, solubility assessment, self-association potential, affinity determination and epitope binning. In addition, cell-based assays were developed to assess the functional potency of the lead molecules. The production and characterization were conducted in record time and enabled prioritization of top leads to progress towards manufacturing cell line generation. The FairJourney team was very responsive to our needs, provided helpful technical advice where needed, and was a pleasure to work with.”
Vahe Bedian
Viridian Therapeutics
“FairJourney Biologics was founded by a group of scientists that have a significant track record in generating therapeutic antibodies to industry standards. They have consistently impressed us with their speed and expertise.”
Mark Throsby
CSO, Merus

Stay Updated

Subscribe to our newsletter and never miss our latest events, news, etc.

This site uses cookies to provide you with a great user experience. By using our website, you accept our use of cookies.